140 related articles for article (PubMed ID: 30053015)
21. Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance Strategies.
Zhou S; Liu S; Zhang L; Guo S; Shen J; Li Q; Yang H; Feng Y; Liu M; Lin SH; Xi M
Ann Surg Oncol; 2018 Nov; 25(12):3639-3646. PubMed ID: 30194608
[TBL] [Abstract][Full Text] [Related]
22. Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma: A Propensity-Matched Analysis.
Hsu HY; Chao YK; Hsieh CH; Wen YW; Chang HK; Tseng CK; Liu YH
Ann Thorac Surg; 2016 Nov; 102(5):1687-1693. PubMed ID: 27457831
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant chemotherapy may not benefit esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy.
Chen MQ; Lin QL; Chen YG; Guo JH; Xu BH; Tian Y
J Chin Med Assoc; 2017 Oct; 80(10):636-643. PubMed ID: 28716602
[TBL] [Abstract][Full Text] [Related]
24. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern.
Bao Y; Liu S; Zhou Q; Cai P; Anfossi S; Li Q; Hu Y; Liu M; Fu J; Rong T; Li Q; Liu H
Radiat Oncol; 2013 Oct; 8():241. PubMed ID: 24139225
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment Primary Tumor Stage is a Risk Factor for Recurrence in Patients with Esophageal Squamous Cell Carcinoma Who Achieve Pathological Complete Response After Neoadjuvant Chemoradiotherapy.
La Mendola R; Bencivenga M; Torroni L; Alberti L; Sacco M; Casella F; Ridolfi C; Simoni N; Micera R; Pavarana M; Verlato G; Giacopuzzi S
Ann Surg Oncol; 2021 Jun; 28(6):3034-3043. PubMed ID: 33078313
[TBL] [Abstract][Full Text] [Related]
26. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
[TBL] [Abstract][Full Text] [Related]
27. Target volume delineation for radical radiotherapy of early oesophageal carcinoma in elderly patients.
Su J; Zhu S; Liu Z; Zhao Y; Song C
Cancer Radiother; 2017 Feb; 21(1):34-39. PubMed ID: 28041813
[TBL] [Abstract][Full Text] [Related]
28. Concurrent chemoradiotherapy with elective lymph node irradiation for esophageal cancer: a systemic review and pooled analysis of the literature.
Du D; Song T; Liang X; Fang M; Wu S
Dis Esophagus; 2017 Feb; 30(2):1-9. PubMed ID: 26918886
[TBL] [Abstract][Full Text] [Related]
29. PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma.
Yuan H; Tong DK; Vardhanabhuti V; Law SY; Chiu KW; Khong PL
Nucl Med Commun; 2016 Sep; 37(9):947-55. PubMed ID: 27145438
[TBL] [Abstract][Full Text] [Related]
30. [Radiochemotherapy for esophageal cancer: which nodes should be irradiated?].
Créhange G; Quivrin M; Vulquin N; Serre AA; Maingon P
Cancer Radiother; 2014 Oct; 18(5-6):577-82. PubMed ID: 25201634
[TBL] [Abstract][Full Text] [Related]
31. Nodal FDG-PET/CT uptake influences outcome and relapse location among esophageal cancer patients submitted to chemotherapy or radiochemotherapy.
Jimenez-Jimenez E; Mateos P; Ortiz I; Aymar N; Roncero R; Gimenez M; Pardo J; Sabater S
Clin Transl Oncol; 2019 Sep; 21(9):1159-1167. PubMed ID: 30661172
[TBL] [Abstract][Full Text] [Related]
32. A phase III randomized controlled trial comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer: ARMADILLO trial (JCOG1904).
Sasaki K; Nomura M; Kato K; Sakanaka K; Ito Y; Kadota T; Machida R; Kataoka T; Minashi K; Tsubosa Y; Kajiwara T; Fukuda H; Takeuchi H; Mizowaki T; Nishimura Y; Kitagawa Y
Jpn J Clin Oncol; 2024 Jan; 54(1):103-107. PubMed ID: 37801434
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Kato K; Nakajima TE; Ito Y; Katada C; Ishiyama H; Tokunaga SY; Tanaka M; Hironaka S; Hashimoto T; Ura T; Kodaira T; Yoshimura K
Jpn J Clin Oncol; 2013 Jun; 43(6):608-15. PubMed ID: 23585687
[TBL] [Abstract][Full Text] [Related]
34. Salvage endoscopic resection (ER) after chemoradiotherapy for esophageal squamous cell carcinoma: What are the risk factors for recurrence after salvage ER?
Hombu T; Yano T; Hatogai K; Kojima T; Kadota T; Onozawa M; Yoda Y; Hori K; Oono Y; Ikematsu H; Fujii S
Dig Endosc; 2018 May; 30(3):338-346. PubMed ID: 29106753
[TBL] [Abstract][Full Text] [Related]
35. Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary?
Zhao KL; Ma JB; Liu G; Wu KL; Shi XH; Jiang GL
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):446-51. PubMed ID: 20004527
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.
Matsuda S; Takeuchi H; Fukuda K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
Dis Esophagus; 2014; 27(7):654-61. PubMed ID: 23980622
[TBL] [Abstract][Full Text] [Related]
37. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
[TBL] [Abstract][Full Text] [Related]
38. Using pretreatment tumor depth and length to select esophageal squamous cell carcinoma patients for nonoperative treatment after neoadjuvant chemoradiotherapy.
Chao YK; Tseng CK; Wen YW; Liu YH; Wan YL; Chiu CT; Chang WC; Chang HK
Ann Surg Oncol; 2013 Sep; 20(9):3000-8. PubMed ID: 23584515
[TBL] [Abstract][Full Text] [Related]
39. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
40. Patterns and predictors of failure following tri-modality therapy for locally advanced esophageal cancer.
Shaikh T; Zaki MA; Dominello MM; Handorf E; Konski AA; Cohen SJ; Shields A; Philip P; Meyer JE
Acta Oncol; 2016; 55(3):303-8. PubMed ID: 26581671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
